Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA commissioner nominee questions do not address dietary supplement issues.

This article was originally published in The Tan Sheet

Executive Summary

PEDIATRIC INDICATIONS, CFC INHALERS AMONG OTC-RELATED ISSUES ADDRESSED in the list of questions forwarded by Senate Labor & Human Resources Committee Chairman James Jeffords (R-Vt.) to FDA Commissioner-nominee Jane Henney, MD, on July 31. The drug issues raised among the list of 140 questions posed in preparation for Henney's confirmation hearing focus almost exclusively on prescription concerns. However, there is overlap with OTCs on some issues, such as pediatric research requirements and the use of chlorofluorocarbons in metered-dose inhalers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel